Moxonidin 1 A Pharma (Moxonidine)

Moxonidine is an antihypertensive agent that acts on central imidazoline I1 receptors to control elevated blood pressure.

• Essential hypertension: lowers systolic and diastolic blood pressure in patients with primary hypertension.
• Isolated systolic hypertension: helps achieve target systolic pressure when isolated elevation is present.
• Hypertension in patients intolerant to other agents: provides an alternative mechanism of action for blood‑pressure control.

• Moxonidine selectively stimulates central imidazoline I1 receptors, which reduces sympathetic nervous system outflow. This leads to decreased peripheral vascular resistance and lower heart rate, resulting in a reduction of systemic arterial blood pressure without significant direct cardiac effects.

Moxonidine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Dry mouth: sensation of reduced salivation.
• Fatigue: feeling of tiredness or lack of energy.
• Dizziness: light‑headed feeling, especially on standing.
• Headache: mild to moderate cranial pain.
• Nausea: upset stomach or urge to vomit.
• Peripheral edema: mild swelling of the lower limbs.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure requiring medical attention.
• Bradycardia: abnormally low heart rate.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Allergic reactions: rash, itching, or swelling of face and throat.
• Syncope: sudden loss of consciousness.
• Renal impairment: worsening kidney function in susceptible individuals.

Before initiating therapy, clinicians should assess patient history and monitor for potential risks.

• Cardiovascular disease: evaluate for existing heart conditions before use.
• Renal impairment: adjust monitoring in patients with reduced kidney function.
• Hepatic disease: consider liver function tests prior to treatment.
• Pregnancy and lactation: use only if potential benefit justifies potential risk.
• Concomitant antihypertensives: monitor for additive blood‑pressure lowering effects.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Moxonidine may interact with other medicines that influence blood pressure or sympathetic activity.

Major Interactions (Avoid)

• Combined use with other central antihypertensives (e.g., clonidine) may cause excessive hypotension.
• Potent CYP2D6 inhibitors: may increase plasma concentrations of moxonidine.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance orthostatic hypotension; monitor electrolytes.

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect.
• Beta‑blockers: additive heart‑rate lowering; observe for bradycardia.